- Home
- ACON vs ENVB Comparison
ACON vs ENVB Comparison
Compare ACON & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACON | ENVB |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.0M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | ACON | ENVB |
|---|---|---|
| Price | $2.48 | $2.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $23.00 | ★ $120.00 |
| AVG Volume (30 Days) | 96.5K | ★ 267.4K |
| Earning Date | 01-01-0001 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | $71.77 | N/A |
| Revenue Next Year | $80.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.61 | $0.56 |
| 52 Week High | $21.31 | $13.25 |
Technical Indicators
Market Signals| Indicator | ACON | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 32.58 | 31.76 |
| Support Level | $2.34 | $1.96 |
| Resistance Level | $7.98 | $4.29 |
| Average True Range (ATR) | 0.20 | 0.22 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 25.49 | 7.34 |
Price Performance
Historical ComparisonAbout ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.